Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20031424 | 1.00 | USP30 (1.00) | USP30 | |
| SCHEMBL22126588 | 1.00 | USP30 (1.00) | USP30 | |
| SCHEMBL22126615 | 0.85 | USP30 (1.00) | USP30 | |
| SCHEMBL22126618 | 0.85 | USP30 (1.00) | USP30 | |
| SCHEMBL29546240 | 0.85 | USP30 (1.00) | USP30 | |
| SCHEMBL22126635 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL29546645 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL29546098 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL20031589 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL22126596 | 0.82 | USP30 (1.00) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-25 | — | — | US | disclosed |
| WO-2018060742-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP1, USP28 | USP30 1/4885 |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | USP30 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.